Navigation Links
Gene Therapy Shows Promise for Rare Children's Brain Disorder
Date:12/19/2012

By Amy Norton
HealthDay Reporter

WEDNESDAY, Dec. 19 (HealthDay News) -- Gene therapy could offer a safe option for treating children with a rare degenerative brain disease, a preliminary study suggests.

The condition, known as Canavan disease, is caused by a mutation in the ASPA gene, which codes for an enzyme called aspartoacylase. Without that enzyme, a chemical known as N-acetylaspartic acid (NAA) builds up in the brain and prevents nerve cells from developing their normal protective sheath. Eventually, the brain degenerates into spongy tissue with fluid-filled spaces.

Canavan disease is rare, with an estimated 600 cases worldwide, according to Paola Leone, the lead researcher on the new study and an associate professor of cell biology at the University of Medicine and Dentistry of New Jersey in Stratford, N.J.

Both parents have to carry the mutated gene for a child to be affected, and the disease is most common among people of Ashkenazi Jewish heritage.

Babies born with Canavan disease never develop normal movement and thinking abilities. They have weak and stiff muscles, suffer seizures, and have problems eating and even supporting their head. (The disorder causes the head to become unusually large.)

Some children with Canavan disease live into their teens or 20s, but most die before their 10th birthday.

"Fifteen years ago, there was no hope for these children," Leone said.

Back in 2001, though, U.S. regulators gave researchers the go-ahead to study a gene therapy method developed by scientists at the University of North Carolina School of Medicine.

The tactic involved inserting a normal copy of the ASPA gene into a non-infectious virus. That gene-carrying virus, or vector, was then infused directly into the brains of children with Canavan disease, in an attempt to override the defective gene.

Over the course of a few years, the researchers treated 13 children in all, and about a decade later, all are still alive, Leone said.

In general, the gene therapy cut the children's brain levels of NAA (the chemical that goes out of control in Canavan), and slowed down their brain tissue degeneration. It also boosted their quality of life, Leone and her colleagues report in the Dec. 19 issue of the journal Science Translational Medicine.

That included small improvements in the children's muscle rigidity, sleep quality, ability to move and attentiveness. Some children started having fewer seizures.

Not all of the kids benefited equally, though, and age at treatment seems to be key.

Because no one knew how the gene therapy would work, the first several children who received it were older -- about 5 years old, on average -- and in a further state of brain degeneration. They showed the least improvement.

But as the trial continued, regulators let Leone's team treat younger children; the last few were 16 months old, on average, and included a 3-month-old. It was those younger children who showed the most benefit in terms of symptoms.

"The therapy should start as early in life as possible," Leone said.

Gene therapy, for any condition, is still experimental; no form of it is approved for use in the United States. The whole field suffered a huge setback in 1999, when a teenager participating in a clinical trial of gene therapy died from a severe immune system reaction to the cold virus used to deliver the gene.

The virus used in the current study was of a different type, considered unlikely to trigger an immune system response. None of the children had a serious immune reaction to the therapy -- though one child developed a fever and another a brain abscess after the initial surgery to infuse the gene.

"The safety findings, to me, are the most important part," said Dr. Maria Escolar, director of the program for the study of neurodevelopment in rare disorders at Children's Hospital of Pittsburgh.

The improvements in children's actual functioning were small, Escolar noted. And one problem, she said, is that there are no good "natural history" studies on kids with Canavan disease. That is, researchers don't fully understand the variance in how children with the disease naturally fare.

It's hard to know how much of the symptom improvement, and overall survival, was due to the gene therapy itself, Escolar said. Advances in how doctors care for kids' complications, such as pneumonia, might have affected survival rates.

Still, Escolar said, "the safety findings, alone, are a huge step forward."

Since this trial began, scientists have also made advances in the viral vectors that could be used for gene therapy. Better ones, that may not need to be directly infused into the brain, are under study in animals -- and close to being studied in humans, Escolar noted.

"Now this study needs to be repeated using better vectors, along with better natural history data," Escolar said.

Gene therapy is not the only approach to Canavan under study, said Morris Baslow, a scientist at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, N.Y.

Other research groups, he said, are trying to better understand how the chemical NAA works in the brain, and hopefully come up with other approaches to treat Canavan disease, including medications.

When it comes to gene therapy, Baslow agreed that it should start very early, soon after birth. He also said the "ideal" method would be to use a viral vector that specifically targets brain cells called oligodendrocytes -- which are responsible for making the protective sheaths around nerves.

Leone agreed that that type of vector would be better. But it doesn't exist yet.

Ultimately, a combination of therapies may be needed to best treat, or even cure, Canavan disease. "Our feeling is, in the future, gene therapy in association with medication that targets the metabolism of [brain] cells will be the cure," Leone said.

More information

Learn more about Canavan disease from the Canavan Research Foundation.

SOURCES: Paola Leone, Ph.D., associate professor, cell biology, University of Medicine and Dentistry of New Jersey, Stratford, N.J.; Morris Baslow, Ph.D., staff scientist, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, N.Y.; Maria L. Escolar, M.D., director, program for the study of neurodevelopment in rare disorders, Children's Hospital of Pittsburgh; Dec. 19, 2012, Science Translational Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. People with HIV hospitalized less often since combination antiretroviral drug therapy introduced
2. Shaft Medical San Diego now offers micro needle sclerotherapy to treat scary “spider” veins.
3. Churchview Supportive Living to Host Music Therapy Informational Program
4. UAlberta medical researchers discover new potential chemotherapy
5. New hormone therapy shows promise for menopausal symptoms in animal model
6. Older and younger chronic leukemia patients may need different therapy
7. Novel test identifies patients most likely to benefit from ALK inhibition therapy
8. Combo Therapy May Help Ease Sleep Apnea at High Altitude
9. Potential gene therapy approach to sickle cell disease highlighted at American Society of Hematology
10. Dr. Farshchian: Labrum Tear is Now Being Treated With Cell Therapy at the Center for Regenerative Medicine Using
11. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Therapy Shows Promise for Rare Children's Brain Disorder
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: